AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12415026
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 2 months
Trial: 10754618
Drug: Clevidipine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevidipine 20 min infusion
Trial: 10754618
Drug: Clevidipine 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevidipine 24 h infusion
Trial: 8771866
Drug: beta‐1,3‐D‐glucan gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐1,3‐D‐glucan gel
Trial: 1474987
Drug: Fenticonazole powder
RxNorm normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenticonazole powder (antifungal treatment)
Trial: 6726012
Drug: HLI (Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLI (Human leukocyte interferon) ophthalmic drops (2.4 x 10^6 IU/ml, 50,000 units per drop, administered two times a day for five days)
Trial: 6726012
Drug: Placebo (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (commercial artificial tear solution)
Trial: 26064048
Drug: AOM 400
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AOM 400 (400 mg once-monthly)
Trial: 26064048
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole (10-30 mg/d)
Trial: 26064048
Drug: AOM 50
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AOM 50 mg (subtherapeutic dose)
Trial: 21456040
Drug: DBT-enhanced habit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBT-enhanced habit reversal treatment (HRT)
Trial: 16453051
Drug: Oral crystalline
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral crystalline cyanocobalamin (1,000 microgram per day for at least 1 month)
Trial: 12910570
Drug: Glucosamine (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine (alone and in combination with chondroitin)
Trial: 11502782
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d oral L-carnitine
Trial: 11502782
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d oral L-carnitine
Trial: 9422900
Drug: Prone knee‐chest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prone knee‐chest position with 3 ml of 0.5% bupivacaine
Trial: 9422900
Drug: Supine side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine side horizontal position with 3 ml of 0.5% bupivacaine
Trial: 8124913
Drug: 3 intravenous
RxNorm normalized name: Ammonia N 13 Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intravenous pulses of 1000 mg methylprednisolone (MP) on alternate days during the first week
Trial: 8124913
Drug: 3 oral
RxNorm normalized name: Cytra-3 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 oral pulses of 100 mg prednisolone
Trial: 3693807
Drug: Timolol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (beta-adrenergic blocker)
Trial: 18363758
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied twice daily for 2 weeks, then to both sides for 6 weeks
Trial: 18363758
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied to L-sides after initial treatment on P-sides
Trial: 18363758
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied to P-sides
Trial: 18363758
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied to L-sides
Trial: 16597037
Drug: Routine methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine methods (psychotherapy, daub narcotic to glans of penis, and medication for chronic prostatitis)
Trial: 14678093
Drug: L-arginine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (12 g orally daily for up to 5 days)
Trial: 3594133
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue biological adhesive system (BAS) applied in Group I (42 patients)
Trial: 31578136
Drug: Zinc bisglycinate
RxNorm normalized name: Citrated zinc bisglycinate
DrugBank: Zinc glycinate (DB14493)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc bisglycinate (15 mg elemental zinc)
Trial: 27485028
Drug: Hydrocortisone 3
RxNorm normalized name: hydrocortisone 3.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 3 mg
Trial: 27485028
Drug: Hydrocortisone 6
RxNorm normalized name: hydrocortisone 6.67 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 6 mg
Trial: 27485028
Drug: Hydrocortisone 12
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 12 mg
Trial: 27485028
Drug: Hydrocortisone 24
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 24 mg
Trial: 27485028
Drug: Hydrocortisone with
RxNorm normalized name: Hydrocortisone with Aloe
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone with RU486 (GR antagonist)
Trial: 24999075
Drug: Levonorgestrel intrauterine
RxNorm normalized name: Levonorgestrel Intrauterine System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel intrauterine device (LNG-IUD) + metformin
Trial: 8215491
Drug: Oral cyclosporine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine, 2.5 mg/kg per day
Trial: 8215491
Drug: Oral cyclosporine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine, 1.25 mg/kg per day
Trial: 8215491
Drug: Oral cyclosporine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine, 3.75 mg/kg per day
Trial: 3317328
Drug: Cefonicid administered
RxNorm normalized name: cefonicid
DrugBank: Cefonicid (DB01328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefonicid administered once daily, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Trial: 3317328
Drug: Cefazolin administered
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administered every eight hours, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Trial: 31804741
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 1000 mg intravenous, administered two weeks apart
Trial: 21406695
Drug: Superoxidized aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superoxidized aqueous solution
Trial: 18982248
Drug: Tablet administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered 45 min before food (pre-feed)
Trial: 18982248
Drug: Tablet administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered on an empty stomach (fasted)
Trial: 18982248
Drug: Tablet administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered after food (fed)
Trial: 18982248
Drug: Tablet administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered pre-feed (in six volunteers)
Trial: 9589652
Drug: rhGH (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.1 mg/kg.day)
Trial: 19436670
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (CC) 8 mg once daily, increased to 16 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Trial: 19436670
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate (AML) 5 mg once daily, increased to 10 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Trial: 15196586
Drug: Metformin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin IR tablet (500 mg)
Trial: 11417922
Drug: Bitemporal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitemporal treatment (after right unilateral treatment failure)
Trial: 444956
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg thrice daily for seven days)
Trial: 25240012
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine intracervical injection 5 min prior to LNG-IUS insertion
Trial: 25240012
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, 400 mg) 1 h prior to LNG-IUS insertion
Trial: 23099972
Drug: Topical/intracameral anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical/intracameral anesthesia (group 1)
Trial: 17903693
Drug: Manidipine 10
RxNorm normalized name: manidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 10 mg every day
Trial: 17903693
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg every day
Trial: 15649162
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (100 mg.kg(‐1) after induction, 100 mg.kg(‐1) in pump prime, 100 mg.kg(‐1) after weaning from bypass)
Trial: 15649162
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aprotinin and tranexamic acid (same dosages as above)
Trial: 12237596
Drug: 1-day intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Trial: 12237596
Drug: 3-day intramuscular
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Trial: 1324238
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg/day
Trial: 6831819
Drug: gallopamil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil (50 mg)
Trial: 6831819
Drug: propafenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propafenone (150 mg)
Trial: 3793333
Drug: nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (10 mg)
Trial: 3793333
Drug: verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (80 mg)
Trial: 6831819
Drug: quinidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinidine (250 mg)
Trial: 27740721
Drug: MF-MDI 50
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-MDI 50 mcg BID
Trial: 27740721
Drug: MF-MDI 100
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-MDI 100 mcg BID
Trial: 27740721
Drug: MF-MDI 200
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-MDI 200 mcg BID
Trial: 25857939
Drug: Stretching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching treatment with a prefabricated orthosis and stretching exercises
Trial: 25857939
Drug: Strengthening treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthening treatment with a prefabricated orthosis, stretching, and strengthening exercises
Trial: 20419494
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 320 mg PO
Trial: 20419494
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg IV + Metoclopramide 20 mg IM (no megestrol acetate)
Trial: 1606999
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg and 100 mg)
Trial: 4075074
Drug: Semantic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantic treatment (4 sessions over one week)
Trial: 4075074
Drug: Semantic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantic treatment (8 sessions over two weeks)
Trial: 4075074
Drug: Phonological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonological treatment (4 sessions over one week)
Trial: 4075074
Drug: Phonological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonological treatment (8 sessions over two weeks)
Trial: 27286139
Drug: Agomelatine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (15 mg/day for patients ≥30 kg and 25 mg/day for patients ≥45 kg)
Trial: 27286139
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) (20 mg/day for participants <30 kg and 30 mg/day for patients ≥30 kg)
Trial: 20685951
Drug: Whole-grain foods
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain foods (3 daily portions)
Trial: 12564610
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg sibenadet via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Trial: 12564610
Drug: Placebo via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Trial: 10627444
Drug: Intensive ALL-type
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines (240 mg/m²) and cyclophosphamide (3 g/m²) with prophylactic cranial irradiation (12 Gy)
Trial: 10627444
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy for patients with less than 70% tumor regression on day 33
Trial: 1735396
Drug: Diclofenac 37.5
RxNorm normalized name: diclofenac 37.5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 37.5 mg or 75 mg
Trial: 1735396
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg or 50 mg
Trial: 1735396
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg or 10 mg
Trial: 3544689
Drug: Verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 80 mg tid
Trial: 3544689
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg bid
Trial: 3544689
Drug: Both 2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 2-dose and 3-dose regimens
Trial: 24456823
Drug: Temsirolimus 25mg
RxNorm normalized name: TEMSIROLIMUS 25MG/ML INJ,SOLN
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 25mg weekly
Trial: 24456823
Drug: Temsirolimus with
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus with megestrol acetate 80 mg bid for three weeks alternating with tamoxifen 20mg bid for three weeks
Trial: 23250594
Drug: Microcurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent therapy (MENS) in addition to standard treatment (n=36)
Trial: 23250594
Drug: Microcurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent therapy (MENS) in combination with cortexin (n=38)
Trial: 23250594
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy using massage and gymnastics (n=31)
Trial: 9180672
Drug: DHEAS (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEAS (7.5 mg)
Trial: 1610024
Drug: Pemirolast 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemirolast 50 mg BID
Trial: 1610024
Drug: Pemirolast 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemirolast 25 mg BID
Trial: 24642702
Drug: Cognitive-based-behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-based-behavioral therapy (CBT)
Trial: 22345500
Drug: Alteplase delivered
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase delivered through a microcatheter embedded within the thrombus at 1 mg per minute, not exceeding 100 mg total
Trial: 17986242
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (20 mug type 6, 40 mug type 11, 40 mug type 16, and 20 mug type 18)
Trial: 11849196
Drug: Dofetilide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide 1.0 mg twice daily for 23 days and once on day 24 (continuous dosing)
Trial: 11849196
Drug: Dofetilide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide 1.0 mg single dose on days 1, 5, 10, 17, and 24 (intermittent dosing)
Trial: 11849196
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo capsules under the same regimen as group 1)
Trial: 7234399
Drug: Cytological examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytological examination of cerebrospinal fluid with histiomonocytic counts greater than 10 M. elements/l and granulocytic peaks greater than 2 M. elements/l
Trial: 23408577
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) therapy for 5 years followed by a 5-year treatment-free period (placebo arm of the FLEX trial)
Trial: 21555291
Drug: Pharmacists providing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists providing information regarding medication's name (93.3%)
Trial: 21555291
Drug: Pharmacists providing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists providing dosage schedule (92.8%)
Trial: 21555291
Drug: Pharmacists advising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists advising daily medication intake (92.6%)
Trial: 12472369
Drug: Thrombolytic drugs
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic drugs
Trial: 11078635
Drug: iobitridol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iobitridol (20 ml)
Trial: 11078635
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline solution (20 ml)
Trial: 9093234
Drug: Suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive therapy for disseminated or invasive fungal infections; details on dosage and duration not available.
Trial: 8287659
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg orally)
Trial: 18398080
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment (LDL-C target of 70 mg/dL or lower, SBP target of 115 mm Hg or lower)
Trial: 18398080
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (LDL-C target of 100 mg/dL or lower, SBP target of 130 mm Hg or lower)
Trial: 9664269
Drug: Sequential pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pneumatic compression (SPC) with a pressure of 40‐60 mmHg for 2 hours/day for 2 weeks
Trial: 2905064
Drug: Suspension therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension therapy (abrupt discontinuation of neuroleptics)
Trial: 30796110
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy (10,000 lux)
Trial: 30796110
Drug: Placebo light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo light therapy
Trial: 12599240
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alpha (4.5 microg/kg per week until hemoglobin concentration >or= 12 g/dL, then 1.5 microg/kg per week)
Trial: 2491362
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg once daily
Trial: 27193497
Drug: Ubiquinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (200 mg/day)
Trial: 23037460
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg intravenously before CECT imaging